ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
19.35
-0.91 (-4.49%)
Mar 31, 2025, 1:39 PM EDT - Market open

ADMA Biologics Statistics

Total Valuation

ADMA Biologics has a market cap or net worth of $4.60 billion. The enterprise value is $4.79 billion.

Market Cap 4.60B
Enterprise Value 4.79B

Important Dates

The last earnings date was Monday, March 3, 2025, after market close.

Earnings Date Mar 3, 2025
Ex-Dividend Date n/a

Share Statistics

ADMA Biologics has 237.62 million shares outstanding. The number of shares has increased by 8.65% in one year.

Current Share Class 237.62M
Shares Outstanding 237.62M
Shares Change (YoY) +8.65%
Shares Change (QoQ) +0.45%
Owned by Insiders (%) 1.94%
Owned by Institutions (%) 87.61%
Float 232.90M

Valuation Ratios

The trailing PE ratio is 23.86 and the forward PE ratio is 27.23. ADMA Biologics's PEG ratio is 1.36.

PE Ratio 23.86
Forward PE 27.23
PS Ratio 11.07
Forward PS 9.62
PB Ratio 13.74
P/TBV Ratio 13.95
P/FCF Ratio 43.59
P/OCF Ratio 40.57
PEG Ratio 1.36
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 32.60, with an EV/FCF ratio of 43.40.

EV / Earnings 24.25
EV / Sales 11.24
EV / EBITDA 32.60
EV / EBIT 34.49
EV / FCF 43.40

Financial Position

The company has a current ratio of 5.97, with a Debt / Equity ratio of 0.24.

Current Ratio 5.97
Quick Ratio 2.76
Debt / Equity 0.24
Debt / EBITDA 0.55
Debt / FCF 0.74
Interest Coverage 9.98

Financial Efficiency

Return on equity (ROE) is 81.65% and return on invested capital (ROIC) is 24.55%.

Return on Equity (ROE) 81.65%
Return on Assets (ROA) 21.24%
Return on Invested Capital (ROIC) 24.55%
Return on Capital Employed (ROCE) 32.09%
Revenue Per Employee $622,561
Profits Per Employee $288,574
Employee Count 685
Asset Turnover 1.04
Inventory Turnover 1.21

Taxes

Income Tax -71.96M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +193.33% in the last 52 weeks. The beta is 0.60, so ADMA Biologics's price volatility has been lower than the market average.

Beta (5Y) 0.60
52-Week Price Change +193.33%
50-Day Moving Average 17.20
200-Day Moving Average 16.83
Relative Strength Index (RSI) 56.20
Average Volume (20 Days) 3,511,263

Short Selling Information

The latest short interest is 15.07 million, so 6.34% of the outstanding shares have been sold short.

Short Interest 15.07M
Short Previous Month 14.23M
Short % of Shares Out 6.34%
Short % of Float 6.47%
Short Ratio (days to cover) 5.30

Income Statement

In the last 12 months, ADMA Biologics had revenue of $426.45 million and earned $197.67 million in profits. Earnings per share was $0.81.

Revenue 426.45M
Gross Profit 219.55M
Operating Income 138.98M
Pretax Income n/a
Net Income 197.67M
EBITDA 147.03M
EBIT 138.98M
Earnings Per Share (EPS) $0.81
Full Income Statement

Balance Sheet

The company has $103.15 million in cash and $82.12 million in debt, giving a net cash position of $21.03 million or $0.09 per share.

Cash & Cash Equivalents 103.15M
Total Debt 82.12M
Net Cash 21.03M
Net Cash Per Share $0.09
Equity (Book Value) 349.02M
Book Value Per Share 1.48
Working Capital 275.87M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $118.67 million and capital expenditures -$8.23 million, giving a free cash flow of $110.45 million.

Operating Cash Flow 118.67M
Capital Expenditures -8.23M
Free Cash Flow 110.45M
FCF Per Share $0.46
Full Cash Flow Statement

Margins

Gross margin is 51.48%, with operating and profit margins of 32.59% and 46.35%.

Gross Margin 51.48%
Operating Margin 32.59%
Pretax Margin 29.48%
Profit Margin 46.35%
EBITDA Margin 34.48%
EBIT Margin 32.59%
FCF Margin 25.90%

Dividends & Yields

ADMA Biologics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -8.65%
Shareholder Yield -8.65%
Earnings Yield 4.11%
FCF Yield 2.29%

Analyst Forecast

The average price target for ADMA Biologics is $22.50, which is 16.28% higher than the current price. The consensus rating is "Strong Buy".

Price Target $22.50
Price Target Difference 16.28%
Analyst Consensus Strong Buy
Analyst Count 4
Revenue Growth Forecast (5Y) 19.77%
EPS Growth Forecast (5Y) 16.31%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

ADMA Biologics has an Altman Z-Score of 13.75 and a Piotroski F-Score of 7.

Altman Z-Score 13.75
Piotroski F-Score 7